Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation.
Xingxing YaoZhanke HeCaolitao QinPenghao ZhangChuyang SuiXiangqian DengYuxin FangGuoxin LiJiaolong ShiPublished in: British journal of cancer (2022)
Our current findings discover that PFKFB3 inhibitors might be effective tools to overcome adjuvant therapy resistance in HER2-positive GC and reshaping the microenvironment by normalising tumour vessels is a novel strategy to overcome trastuzumab resistance.